Learn about DARZALEX FASPRO® + VRd, the latest FDA-approved quad treatment combination for people with newly diagnosed multiple myeloma who are not eligible to receive a stem cell transplant

Sign Up For Support

DARZALEX FASPRO ® is now FDA approved as the first therapy for use alone to treat adults with high-risk smoldering multiple myeloma.

Homepage Banner Desktop Image
About DARZALEX FASPRO® & DARZALEX®What are DARZALEX FASPRO® & DARZALEX®?

What are
DARZALEX FASPRO® & DARZALEX®?

DARZALEX FASPRO® and DARZALEX® are prescription medicines used alone or in combination with one or more treatments for adults with a rare form of blood cancer called multiple myeloma. Read on to learn more
about what DARZALEX FASPRO® and DARZALEX® are indicated to treat.

DARZALEX FASPRO® and DARZALEX® are not chemotherapies. They are targeted
monoclonal antibodies that help slow or stop the progression of multiple myeloma in
several ways.

Both treatments are made up of
daratumumab
(pronounced da-ra-tu-mu-mab ) to treat multiple myeloma.

DARZALEX FASPRO® is also made up of hyaluronidase
(pronounced hy-a-lur-on-i-dase ), which helps daratumumab to be injected into the skin and absorbed in the body.

How daratumumab works to fight multiple myeloma
Three multiple myeloma cells

Multiple myeloma cells, like other types of cancer, can go unrecognized by your body's immune system, which allows the cells to grow.

Daratumumab attaching to the surface of a multiple myeloma cell

Daratumumab attaches itself to the CD38 protein on the surface of multiple myeloma cells, as well as on certain other types of cells such as red blood cells.

Free-floating daratumumab and destroyed pieces of a multiple myeloma cell

Daratumumab directly kills multiple myeloma cells and/
or enables your immune system to identify and destroy them. Because of the way daratumumab works, it may also affect some normal cells.

Who are
DARZALEX FASPRO® and DARZALEX® for?

Woman with baby blue swimsuit sitting in pool lounge chair
Newly diagnosed
Transplant ineligible*

DARZALEX®: in combination with lenalidomide (R) and dexamethasone (d)

DARZALEX FASPRO® or DARZALEX®: in combination with bortezomib (V), melphalan (M), and prednisone (P)

Transplant eligible*

DARZALEX FASPRO®: in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d)

DARZALEX®: in combination with bortezomib (V), thalidomide (T), and dexamethasone (d)

*Newly diagnosed patients who can or cannot receive a type of stem cell transplant that uses their own stem cells.

Previously treated
After ≥1 prior medicines

DARZALEX FASPRO® or DARZALEX®: in combination with lenalidomide (R) and dexamethasone (d)

DARZALEX®: in combination with bortezomib (V) and dexamethasone (d)

DARZALEX FASPRO® or DARZALEX®: in combination with pomalidomide (P) and dexamethasone (d) in patients previously treated with lenalidomide (R) and a proteasome inhibitor (PI)

DARZALEX FASPRO® or DARZALEX®: in combination with carfilzomib (K) and dexamethasone (d)

After ≥3 prior medicines

DARZALEX FASPRO® or DARZALEX® alone: prior medicines included a proteasome inhibitor (PI) and an immunomodulatory agent, or patients who did not respond to a PI and an immunomodulatory agent

Watch the videos below to learn how DARZALEX FASPRO® and DARZALEX® work

Before starting treatment, it’s important to talk with your doctor about what you might expect. You can watch the videos to learn more about how DARZALEX FASPRO® and DARZALEX® work, as well as what to expect.

DARZALEX FASPRO® MOA Video
DARZALEX® MOA Video

MOA=mechanism of action.

NextExperience the DARZALEX® Difference